Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade

Description of Zanolimumab Biosimilar - Anti-CD4 mAb - Research Grade

Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade

Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade: A Promising Antibody for Targeting CD4 in Therapeutic Applications

Introduction

Zanolimumab Biosimilar is a monoclonal antibody (mAb) that specifically targets CD4, a cell surface protein found on T helper cells. It is a biosimilar version of zanolimumab, a therapeutic mAb that has been used in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis. Zanolimumab Biosimilar has been developed as a research grade antibody for studying the structure, activity, and potential therapeutic applications of targeting CD4.

Structure of Zanolimumab Biosimilar

Zanolimumab Biosimilar is a recombinant humanized IgG1 mAb, meaning it has been engineered to have a human-like structure. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable region of the antibody is responsible for binding to the CD4 protein, while the constant region determines the antibody’s effector functions.

The crystal structure of zanolimumab has been determined, revealing that the antibody binds to a specific region on the CD4 protein known as the D1 domain. This binding site is critical for the interaction between CD4 and its ligands, making zanolimumab an effective inhibitor of CD4 function.

Activity of Zanolimumab Biosimilar

Zanolimumab Biosimilar has a high affinity for CD4, with a dissociation constant (Kd) in the nanomolar range. This allows the antibody to bind to CD4 with high specificity and effectively block its function. By binding to CD4, zanolimumab prevents the interaction between CD4 and its ligands, including major histocompatibility complex (MHC) class II molecules and HIV envelope glycoprotein gp120. This inhibition of CD4 function has been shown to have therapeutic benefits in various diseases.

In addition to blocking CD4 function, zanolimumab also has effector functions that can contribute to its therapeutic activity. These include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which involve the recruitment of immune cells and activation of the complement system to destroy target cells. These effector functions may be particularly important in the treatment of diseases where CD4-expressing cells are the target, such as certain types of cancer.

Application of Zanolimumab Biosimilar

Zanolimumab Biosimilar has potential therapeutic applications in a variety of diseases where CD4 is involved, including autoimmune diseases, infectious diseases, and cancer. In autoimmune diseases, zanolimumab can inhibit the function of CD4-positive T cells that are responsible for the abnormal immune response. In infectious diseases, zanolimumab can block the interaction between CD4 and the virus, preventing viral entry into target cells. In cancer, zanolimumab can target and destroy CD4-expressing cancer cells, either through its effector functions or by blocking the interaction between CD4 and growth factors that promote tumor growth.

Zanolimumab Biosimilar is also a valuable research tool for studying the role of CD4 in various diseases. By targeting CD4 with high specificity, zanolimumab can help researchers understand the function of this protein and its involvement in disease processes. Additionally, zanolimumab can be used to screen for potential therapeutic agents that may have a similar mechanism of action as zanolimumab, but with improved efficacy or safety profiles.

Conclusion

Zanolimumab Biosimilar is a promising antibody for targeting CD4 in therapeutic applications. Its high specificity and affinity for CD4, as well as its effector functions, make it a versatile tool for researchers and a

Zanolimumab Biosimilar - Anti-CD4 mAb binds to Human CD4 in indirect ELISA Assay

Immobilized CD4 Protein - T-cell surface glycoprotein CD4(CD4) (cat. No. PX-P4702) at 0.5µg/mL (100µL/well) can bind Zanolimumab Biosimilar - Anti-CD4 mAb (cat. No. PX-TA1152) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 3.124M.

Zanolimumab Biosimilar - Anti-CD4 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.